Impact BioMedical Q1 FY26 net loss widens 79% to $2.28 million
PUBT · 05/12 20:44
Share
Listen to the news
- Impact Biomedical posted a net loss of $2.28 million for quarter ended March 31, 2026, widening 79%.
- Revenue was $7,000, reflecting biotech retail sales of Celios air purification products acquired in February 2025.
- Total costs and expenses climbed to $2.3 million, up 127%, driven by stock-based compensation of $1.44 million.
- Operating cash outflow narrowed to $464,000, while net cash from financing activities was $482,000 from related-party borrowings from DSS.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022512), on May 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved